Serum drug levels and medication adherence in heart failure: A comparative cohort analysis

Libor Jelinek1, Martin Modrak2, Jan Vaclavik3

  • 1Department of Exercise Medicine and Cardiovascular Rehabilitation, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic.

Insights

Medication adherence in heart failure patients was assessed using serum drug levels. While most patients were adherent, the 2020 cohort showed lower adherence compared to 2018, despite similar heart failure severity.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Medication adherence is crucial for managing chronic heart failure (HF).
  • Direct methods like serum drug level testing offer objective adherence assessment.
  • Understanding adherence trends over time is important for patient outcomes.

Purpose of the Study:

  • To compare medication adherence in two heart failure patient cohorts.
  • To evaluate changes in adherence between 2018 and 2020 using serum drug levels.
  • To identify factors associated with adherence in HF patients.

Main Methods:

  • A prospective, monocentric registry (LEVEL-CHF) was used.
  • Two cohorts of stable HF with reduced ejection fraction patients were enrolled in 2018 and 2020.
  • Serum drug levels were employed for direct adherence detection.

Main Results:

  • 81% of patients were fully adherent; 19% showed varying degrees of non-adherence.
  • The 2020 cohort demonstrated significantly lower medication adherence than the 2018 cohort (P<0.01).
  • Increased BMI and fasting glycemia were observed in 2020 compared to 2018.

Conclusions:

  • Most heart failure patients exhibited full medication adherence.
  • Serum drug level testing is an effective adherence assessment tool in clinical practice.
  • No significant clinical differences were found between adherent and non-adherent HF patients.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
488
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
318
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
360
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
303
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
38
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
115